IL310941A - Methods for the treatment of cancer associated with immunosuppressive B cells - Google Patents
Methods for the treatment of cancer associated with immunosuppressive B cellsInfo
- Publication number
- IL310941A IL310941A IL310941A IL31094124A IL310941A IL 310941 A IL310941 A IL 310941A IL 310941 A IL310941 A IL 310941A IL 31094124 A IL31094124 A IL 31094124A IL 310941 A IL310941 A IL 310941A
- Authority
- IL
- Israel
- Prior art keywords
- bispecific antibody
- binds
- immunoglobulin
- heavy chain
- light chain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163236953P | 2021-08-25 | 2021-08-25 | |
| PCT/US2022/041395 WO2023028159A1 (en) | 2021-08-25 | 2022-08-24 | Methods of treating cancers associated with immunosuppressive b cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL310941A true IL310941A (en) | 2024-04-01 |
Family
ID=85322012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL310941A IL310941A (en) | 2021-08-25 | 2022-08-24 | Methods for the treatment of cancer associated with immunosuppressive B cells |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240392000A1 (https=) |
| EP (1) | EP4392062A4 (https=) |
| JP (1) | JP2024534116A (https=) |
| KR (1) | KR20240055016A (https=) |
| CN (1) | CN118139639A (https=) |
| AU (1) | AU2022332971A1 (https=) |
| CA (1) | CA3229824A1 (https=) |
| IL (1) | IL310941A (https=) |
| WO (1) | WO2023028159A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220159989A (ko) | 2020-02-26 | 2022-12-05 | 바이오그래프 55, 인크. | C19 c38 이중특이적 항체 |
| AU2024239150A1 (en) | 2023-03-21 | 2025-10-02 | Biograph 55, Inc. | Cd19/cd38 multispecific antibodies |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6594855B2 (ja) * | 2013-03-15 | 2019-10-23 | ゼンコア インコーポレイテッド | ヘテロ二量体タンパク質 |
| EA037548B1 (ru) * | 2015-06-24 | 2021-04-12 | Янссен Байотек, Инк. | Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38 |
| WO2021173844A1 (en) * | 2020-02-26 | 2021-09-02 | Biograph 55, Inc. | C19 c38 bispecific antibodies |
-
2022
- 2022-08-24 IL IL310941A patent/IL310941A/en unknown
- 2022-08-24 AU AU2022332971A patent/AU2022332971A1/en active Pending
- 2022-08-24 EP EP22862039.9A patent/EP4392062A4/en active Pending
- 2022-08-24 JP JP2024511969A patent/JP2024534116A/ja active Pending
- 2022-08-24 CA CA3229824A patent/CA3229824A1/en active Pending
- 2022-08-24 WO PCT/US2022/041395 patent/WO2023028159A1/en not_active Ceased
- 2022-08-24 KR KR1020247009786A patent/KR20240055016A/ko active Pending
- 2022-08-24 CN CN202280071314.3A patent/CN118139639A/zh active Pending
- 2022-08-24 US US18/685,489 patent/US20240392000A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3229824A1 (en) | 2023-03-02 |
| US20240392000A1 (en) | 2024-11-28 |
| AU2022332971A1 (en) | 2024-03-21 |
| EP4392062A4 (en) | 2025-11-19 |
| WO2023028159A1 (en) | 2023-03-02 |
| JP2024534116A (ja) | 2024-09-18 |
| CN118139639A (zh) | 2024-06-04 |
| KR20240055016A (ko) | 2024-04-26 |
| EP4392062A1 (en) | 2024-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021515568A5 (https=) | ||
| JP2024175003A5 (https=) | ||
| JP2021515565A5 (https=) | ||
| IL276830B1 (en) | Anti-claudin 18.2 antibodies and their uses | |
| JP2021533726A5 (https=) | ||
| WO2019186273A4 (en) | Subcutaneous dosing of anti-cd38 antibodies | |
| IL310941A (en) | Methods for the treatment of cancer associated with immunosuppressive B cells | |
| RU2007145419A (ru) | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами | |
| JP2020522254A5 (https=) | ||
| RU2008106760A (ru) | Антитела против сd26 и способы их применения | |
| RU2014103784A (ru) | Антитело, блокирующее agr2, и его применение | |
| WO2020257789A3 (en) | Anti-tim-3 antibodies | |
| JP2021512652A5 (https=) | ||
| JP2023522417A5 (https=) | ||
| WO2023225528A3 (en) | Anti-cd84 antibodies and uses thereof | |
| JP2024533457A5 (https=) | ||
| JP2023546293A5 (https=) | ||
| NZ778352B2 (en) | Tumor-targeted agonistic cd28 antigen binding molecules | |
| NZ778352A (en) | Tumor-targeted agonistic cd28 antigen binding molecules | |
| NZ761020A (en) | Cd38 modulating antibody | |
| NZ761838A (en) | Cd38 antibody | |
| NZ760342A (en) | Cd38 modulating antibody | |
| NZ761020B2 (en) | Cd38 modulating antibody | |
| JP2024540536A5 (https=) | ||
| NZ761838B2 (en) | Cd38 antibody |